// App-Quantinova.ai

2536 : Risks and benefits of phase I liver dysfunction studies: Should patients with severe liver dysfunction be included in these trials?

Researchers

Presenter

  • Selena Juarez Stuart

Principal Investigators

  • John Sarantopoulos

  • Steven D. Weitman

  • Anand B. Karnad

  • Devalingam Mahalingam

  • Sukeshi R. Patel

Medical Centers

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, TXCancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved